MEN’S HEALTH QUARTERLY
Longevity

Sermorelin for Weight Loss: What the Evidence Shows and Does Not

The fat-loss numbers quoted for sermorelin belong to other drugs in other patients. Here is what each study tested.

Words by the editors ·

Sponsored

There is no good evidence that sermorelin causes weight loss. A PubMed search on October 26, 2026 for sermorelin with body composition, fat or obesity returned four records: two sports-medicine reviews, a review of growth hormone secretagogues in hypogonadal men, and a retrospective series that measured IGF-1, not weight.1 The fat-loss data people quote belong to a related drug, tesamorelin, and to growth hormone itself, both tested in other groups. Sermorelin is also not FDA-approved for weight loss, and no sermorelin label was listed in a DailyMed search on October 24, 2026.7

In brief

  • A PubMed search on October 26, 2026 found no randomized trial of sermorelin for weight or fat loss.1
  • Tesamorelin, a related drug, reduced visceral fat in trials of people with HIV and of obese people with low growth hormone, and its label says it is not indicated for weight loss.234
  • Low-dose growth hormone reduced visceral fat in a 10-trial meta-analysis of 420 obese adults, with a small rise in fasting glucose.5
  • Compounded sermorelin is not FDA-approved, and no sermorelin label was listed in DailyMed.67

What is the idea behind sermorelin for weight loss?

Sermorelin is a copy of growth hormone-releasing hormone, the signal that tells the pituitary to release growth hormone.8 Growth hormone can reduce fat and build lean tissue, so the argument runs that nudging your own release should do the same. A 2020 review of growth hormone secretagogues said these compounds are potent growth hormone and IGF-1 stimulators that may improve body composition, then added that a paucity of clinical data limits what can be concluded.9 The leap from a hormone signal to a lower scale weight is where the evidence stops.

What did the only sermorelin study in adults measure?

The adult series we found reviewed men on testosterone who took 100 micrograms of sermorelin with two other peptides three times daily. Only 14 met the study's compliance criteria, and IGF-1 rose from 159.5 to 239.0 ng/mL.10 It was a retrospective chart review of a combination without a control group, and IGF-1 is a lab marker, not a measure of fat. A broader review of these agents also noted few long-term controlled studies and some concern about blood glucose.11

What do the closest drugs show?

EvidenceWho was studiedResultCaveat
Tesamorelin, 2007 trial2412 people with HIV and abdominal fat, 26 weeksVisceral fat fell 15.2% vs a 5.0% rise on placeboNot people without HIV
Tesamorelin, 2014 trial1250 people with HIV and abdominal fat, 6 monthsVisceral fat changed by -34 cm2 vs +8 cm2 on placeboAuthors called it preliminary; fasting glucose rose at 2 weeks
Tesamorelin, 2012 trial360 abdominally obese people with reduced growth hormone secretion, 12 monthsVisceral fat -16 vs +19 cm2; no significant change in subcutaneous fatSelected for low growth hormone; not weight loss as an outcome
Low-dose growth hormone, meta-analysis510 randomized trials, 420 obese adults without deficiencyVisceral fat down (SMD -0.34); thigh muscle area up 6.33 cm2Fasting glucose rose by 4.18 mg/dL; actual growth hormone, not sermorelin

Even for tesamorelin, the benefit is fat in the abdomen, not weight. The EGRIFTA SV label says it is indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management because it has a weight neutral effect.4 Our comparison of sermorelin and tesamorelin sets out why one drug's trials cannot be transferred to the other.

Does growth hormone itself cause weight loss in healthy men?

A meta-analysis of 11 placebo-controlled trials in 254 healthy young adults found that growth hormone increased lean body mass and decreased fat mass, but did not improve muscle strength or aerobic capacity over weeks to months.13 That is real growth hormone at studied doses, not a peptide that prompts your pituitary, and the study measured body composition, not how much a person weighs. Nothing in it shows that sermorelin produces the same change.

Why do "sermorelin weight loss" pages promise more?

Search results for the query are dominated by clinic marketing and near-duplicate pages across unrelated domains. The tesamorelin and growth hormone findings above get borrowed for sermorelin, and the missing sermorelin trial goes unmentioned. A 2026 review of peptides acting on the growth hormone axis warned about uncertain composition and dosing in unregulated supply chains and about a gap between clinical evidence and self-administration.14

What are the risks to weigh?

The side effects reported so far are in sermorelin side effects: what studies report, and whether it is worth pursuing at all is covered in is sermorelin worth it.

What does have evidence for losing weight?

In a randomized trial in Italy, 110 obese men with ED who lost weight and exercised more improved their erectile function scores, while a control group given general advice did not change.15 Our feature on exercise, weight and sexual health walks through that trial and what it means for men weighing treatment. Weight management is a conversation for a clinician who can check thyroid, sleep, glucose and medicines.

This section is sponsored: we have a financial relationship with Vea Health. It is not a recommendation to use sermorelin for weight loss, because the evidence above does not support that.

Vea Health says it offers sermorelin injections prescribed by a licensed clinician after an online health questionnaire, filled by a state-licensed U.S. compounding pharmacy, and that you are not charged unless a clinician approves the prescription.16 The page we loaded does not mention weight loss as a result. Compounded sermorelin is not FDA-approved.6 Tell any prescriber about cancer, pituitary or thyroid conditions, diabetes and every medicine you take.

Bottom line

Sermorelin has no trial showing weight loss. The fat reductions that get cited come from tesamorelin in specific patient groups and from growth hormone itself, and even they concern abdominal fat, with a label that says tesamorelin does not manage weight. Be skeptical of any page promising a result from sermorelin, and take the question to a clinician who can look at your labs.

Important safety information. NAD+ and sermorelin are prescription injections. Compounded versions are not FDA-approved.6 Tell the prescribing clinician about every medication and supplement you take, and about any history of cancer, pituitary or thyroid conditions, or pregnancy. Only a licensed clinician who knows your health history should decide whether a prescription is appropriate for you.

Questions

Does sermorelin help you lose weight?

No trial we found tested it for weight loss. The adult data measured IGF-1, and fat-loss results belong to tesamorelin and growth hormone, studied in other patient groups.

Is sermorelin FDA-approved for weight loss?

No. A DailyMed search on October 24, 2026 listed no sermorelin label, and compounded sermorelin is not FDA-approved.

Does tesamorelin cause weight loss?

The label says it is not indicated for weight loss management because it has a weight neutral effect. It is approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy.

How long does sermorelin take to cause weight loss?

No study gives a timeline because none tested it for weight loss. Any timeline on a clinic page is not backed by a trial we could find.

Also in this edition

Part of our guide: Sermorelin: The Complete Guide

Notes

  1. National Library of Medicine. PubMed search: sermorelin and body composition, fat or obesity. Searched October 26, 2026.
  2. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. PubMed 18057338.
  3. Makimura H, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012. PubMed 23015655.
  4. Theratechnologies. EGRIFTA SV (tesamorelin) prescribing information. DailyMed, U.S. National Library of Medicine.
  5. Sun F, et al. Effects of low-dose growth hormone treatment on obesity: a meta-analysis of randomized controlled trials. Postgrad Med. 2025. PubMed 41036661.
  6. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
  7. Sermorelin search. DailyMed, U.S. National Library of Medicine. Searched October 24, 2026.
  8. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed 18031173.
  9. Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020. PubMed 32257855.
  10. Sigalos JT, et al. Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Am J Mens Health. 2017. PubMed 28830317.
  11. Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018. PubMed 28400207.
  12. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014. PubMed 25038357.
  13. Hermansen K, et al. Impact of GH administration on athletic performance in healthy young adults: a systematic review and meta-analysis of placebo-controlled trials. Growth Horm IGF Res. 2017. PubMed 28514721.
  14. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026. PubMed 42395176.
  15. Esposito K, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004. PubMed 15213209.
  16. Vea Health. Sermorelin intake. Accessed October 9, 2026.